Member Info for Adastra

The fact that Novo Holdings has taken 5% and is intending to increase that holding (joining BioMerieux on the register with its 7%) should not be underestimated. Novo's glowing testimonial to Oxford Nanopore is highly significant - why?

Novo Holdings is a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, one of the world’s largest enterprise foundations.

Novo Holdings is the controlling shareholder of Novo Nordisk and Novozymes (the Novo Group companies). It manages assets of €150bn

Novo Nordisk headquartered in Denmark, Novo Nordisk A/S employs more than 64,000 employees in 80 countries and markets its products in 168 countries. In 2023, Novo Nordisk A/S had revenue of DKK 232,261 million.

Novozymes A/S has more than 6,700 employees worldwide and markets more than 700 products in 140 countries. In 2023, Novozymes A/S had revenue of DKK 17,899 million

Novo is a pathfinder and first mover.

100% safe Australian jurisdiction - not subject to political unrest or rapid regime change!

Proven method of highly economic rare earth/ uranium extraction without the need for extensive traditional mining.

Awaiting final results of increased REE recovery rates seen in bench tests giving lowest cost scale up.

Interesting and massively undervalued if near-term indicators prove correct.

Locked and loaded......

As Edison pointed out:

Cobra has several upcoming catalysts that could provide positive newsflow. It has already de-risked its discovery by identifying ionic REE mineralisation with good metallurgical recovery rates to date. It is continuing to prove up ISR as a recovery method and initial indications for scale are positive. Cobra’s market valuation is well below its peers and, if it successfully achieves its goals this year (notably defining high recoveries in column leach tests, a maiden resource based on ionic mineralisation and a processing pathway with low reagent usage), this could lead to share price appreciation.

Bizarre that so much positive shareholder information is being distributed and the reaction is to drop back to the 120 level at which Novo purchased 5% and continues to load up. Less than 6 weeks till the 3yr IPO anti takeover protection shares expire, 2 big pharmas have already bought in, and now EIT Oxford Llc shows its 3% hand. This is getting very interesting and September should focus analysts attention.

Love quiet overlooked little gems like this. Do the research, take a position and wait for the September interims or action sooner. Just done same with CYK and it's up nicely a few days later.

Cobra looks a little gem.....this Cobra could strike quickly and cause investors to take a little more notice. Well worth time doing the research and following the latest director buy imo.

The fact that Oxford Nano provides the tools to track DNA mutations is pivotal in containing any future pandemic. Today it is Mpox that's WHO concern but in the background Avian flu mutation is of growing concern. ONT is a must-have in my pf and accumulating on any pull back.

Accumulating as the price swing starts to reflect the potential in the next RNS. Quietly does it........

Interims and end of takeover protection looms. Time to sit back and watch the action. Novacyt reacted swiftly to WHO Mpox alert but it's only sub £100m MCap - reaction here muted but adds to the near-term positives in the mix.

Just serves to focus the investment community on the huge ip value here. AI is running, BI (Biological Intelligence) is only on the starting line and Oxford Nano makes all the tools. When that fact is realized by other than the few, this will go vertical. Especially given its built-in independence protection ends in 6 weeks time.......dyor and watch this space.

The fact that it's at current market price indicates traction.

The fact that a service supplier will be converting his outstanding fees aggregating to £17,700 into equity at 5.9p per share, representing 300,000 Ordinary Shares is a nice vote of confidence at this stage. Insight is invaluable.

Thanks for that

Question. Why does form indicate previous holding as blank and resulting holding of transaction as 4.7%?

G42 Investments AI Holding Limited enters the picture with 4.7%.

This is starting to get interesting as we are only 6 weeks away from expiration of the IPO built-in takeover protection on October 5th. BioMeriuex, Novo and now a UAE holder.

THIS is why we need the rapid DNA analysis of Oxford Nano. Biological vigilance.

Totally under-the-radar and could very easily surprise with indication of traction. All the pointers are present, just needs a positive uptake RNS that could land anytime.

This looks like the beginnings of increasing BIG Pharma interest in the run up to expiration of anti-takeover protection which ends October 5th.

BioMerieux hold 7% now Novo hold 5%...... next please..??

Pay £1.20 and joint big pharmas Novo who paid £1.20 last weey for £50m+ and BioMerieux [who paid £2.39 for 7% in October]. They can see that Oxford Nano is providing the picks and shovels to transform the Healthcare industry.

Anti-takeover protection built into the IPO three years ago expires on October 5th and as the CEO constantly tells us, predatory interest abounds. Company has a great cash runway to 2027 and its products are being used in multiple jurisdictions for variety of potential blockbusters.